CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype

Biochemical and Biophysical Research Communications

Volumn 432, Issue 2, 2013, Pages 333-338

  Kang, Kyu Sub ^a   Choi, Yoon Pyo ^a   Gao, Ming Qing ^b   Kang, Suki ^a   Kim, Baek Gil ^a   Lee, Joo Hyun ^a   Kwon, Mi Jeong ^c   Shin, Young Kee ^d   Cho, Nam Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b NORTHWEST A F UNIVERSITY   (China)

^c Kyungpook National University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

CD24; CXCR4; Epithelial mesenchymal transition; Invasiveness; Ovary cancer

Indexed keywords

BETA1 INTEGRIN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBRONECTIN; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CELL SUBPOPULATION; CHEMOTAXIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TISSUES; WESTERN BLOTTING;

ANTIGENS, CD24; ANTIGENS, CD29; CELL ADHESION; CHEMOKINE CXCL12; CHEMOTAXIS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84875269869     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.102     Document Type: Article

References (41)

1. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
2. Grunert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4:657-665.
3. Ahmed N., Abubaker K., Findlay J., et al. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 2010, 10:268-278.
4. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
5. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
6. Marhaba R., Klingbeil P., Nuebel T., et al. CD44 and EpCAM: cancer-initiating cell markers. Curr. Mol. Med. 2008, 8:784-804.
7. Li C., Lee C.J., Simeone D.M. Identification of human pancreatic cancer stem cells. Methods Mol. Biol. 2009, 568:161-173.
8. Hong S.P., Wen J., Bang S., et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009, 125:2323-2331.
9. Alvero A.B., Chen R., Fu H.H., et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166.
10. Curley M.D., Therrien V.A., Cummings C.L., et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27:2875-2883.
11. Lee J.H., Kim S.H., Lee E.S., et al. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol. Rep. 2009, 22:1149-1156.
12. Kristiansen G., Denkert C., Schluns K., et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 2002, 161:1215-1221.
13. Kristiansen G., Schluns K., Yongwei Y., et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br. J. Cancer 2003, 88:231-236.
14. Kristiansen G., Winzer K.J., Mayordomo E., et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 2003, 9:4906-4913.
15. Kristiansen G., Sammar M., Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J. Mol. Histol. 2004, 35:255-262.
16. Jacob J., Bellach J., Grutzmann R., et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 2004, 4:454-460.
17. Weichert W., Denkert C., Burkhardt M., et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin. Cancer Res. 2005, 11:6574-6581.
18. Lim S.C. CD24 and human carcinoma: tumor biological aspects. Biomed. Pharmacother. 2005, 59(suppl. 2):S351-S354.
19. Chou Y.Y., Jeng Y.M., Lee T.T., et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann. Surg. Oncol. 2007, 14:2748-2758.
20. Sagiv E., Arber N. The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev. Gastroenterol. Hepatol. 2008, 2:125-133.
21. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
22. Choi Y.P., Shim H.S., Gao M.Q., et al. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett. 2011, 307:62-71.
23. Wei X., Dombkowski D., Meirelles K., et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc. Natl. Acad. Sci. USA 2010, 107:18874-18879.
24. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4:540-550.
25. Murakami T., Maki W., Cardones A.R., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002, 62:7328-7334.
26. Barbero S., Bonavia R., Bajetto A., et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 2003, 63:1969-1974.
27. Phillips R.J., Burdick M.D., Lutz M., et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 2003, 167:1676-1686.
28. Dalerba P., Clarke M.F. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007, 1:241-242.
29. Scotton C.J., Wilson J.L., Scott K., et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002, 62:5930-5938.
30. Schabath H., Runz S., Joumaa S., et al. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell Sci. 2006, 119:314-325.
31. Lessan K., Aguiar D.J., Oegema T., et al. CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am. J. Pathol. 1999, 154:1525-1537.
32. Kenny H.A., Kaur S., Coussens L.M., et al. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 2008, 118:1367-1379.
33. Baumann P., Cremers N., Kroese F., et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005, 65:10783-10793.
34. Kwon M.J., Kim S.S., Choi Y.L., et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010, 31:974-983.
35. Iwatsuki M., Mimori K., Yokobori T., et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101:293-299.
36. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
37. Runz S., Mierke C.T., Joumaa S., et al. CD24 induces localization of beta1 integrin to lipid raft domains. Biochem. Biophys. Res. Commun. 2008, 365:35-41.
38. Kaur S., Kenny H.A., Jagadeeswaran S., et al. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am. J. Pathol. 2009, 175:2184-2196.
39. Lathia J.D., Gallagher J., Heddleston J.M., et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432.
40. Trerotola M., Rathore S., Goel H.L., et al. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am. J. Transl. Res. 2010, 2:135-144.
41. Vaillant F., Asselin-Labat M.L., Shackleton M., et al. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68:7711-7717.